Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mayer Rashtian

Clinical Cardiac Electrophysiology Pasadena, CA Medical Doctor

NPI 1104876002 CMS profile 322015

625 S Fair Oaks Ave, Suite 215, Pasadena, CA 91105

Open in the dashboard

General payments

$208,799

1,601 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,624,687 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Mayer Rashtian of Pasadena, CA is reported in the CMS Open Payments database as having received $208,799 across 1,601 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,624,687 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,397 252
2024 General $18,039 238
2023 General $20,483 280
2022 General $39,552 262
2021 General $55,226 235
2020 General $18,603 136
2019 General $43,500 198

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mayer Rashtian
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Mayer Rashtian were reported at $13,397. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Mayer Rashtian Clinical Cardiac Electrophysiology median Middle half National median
2019 $43,500 $2,361 $585–$8,260 $163
2020 $18,603 $993 $247–$4,351 $114
2021 $55,226 $1,185 $326–$4,739 $132
2022 $39,552 $2,073 $554–$6,789 $149
2023 $20,483 $2,568 $759–$8,159 $160
2024 $18,039 $2,557 $703–$7,403 $164
2025 $13,397 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $76,479 211 payments
  2. Janssen Pharmaceuticals, Inc $43,139 78 payments
  3. Sanofi-Aventis U.S. LLC $29,641 32 payments
  4. E.R. Squibb & Sons, L.L.C. $22,406 70 payments
  5. Boston Scientific Corporation $11,596 418 payments
  6. Cardiva Medical, Inc. $5,222 55 payments
  7. Pfizer Inc. $4,220 80 payments
  8. Medtronic, Inc. $2,495 98 payments
  9. Novartis Pharmaceuticals Corporation $2,045 128 payments
  10. Amgen Inc. $1,041 60 payments
  11. Other $10,514 371 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $94,414 45 payments
  2. Consulting Fee $56,615 32 payments
  3. Food and Beverage $43,554 1,465 payments
  4. Travel and Lodging $14,182 56 payments
  5. Education $34 3 payments
Products named General payments · program years 2019–2025
  1. XARELTO $43,141 79 payments
  2. ELIQUIS Cardiovascular $22,018 51 payments
  3. MULTAQ Cardiology/Vascular Diseases $18,737 16 payments
  4. Nanostim Leadleas Pacemaker $12,930 12 payments
  5. MULTAQ Cardiology/Vascular Diseases $10,762 8 payments
  6. AVEIR Structural Heart $6,693 11 payments
  7. Cardiva VASCADE MVP VVCS 6-12F $5,167 51 payments
  8. AVEIR Cardiac Rhythm Management $3,979 22 payments
  9. ELIQUIS Cardiovascular;Metabolic Disease $3,532 54 payments
  10. AVEIR Cardiac Rhythm Management $2,815 11 payments
  11. Other $41,109 1,290 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

10,217

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$6,509,813

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

57.2%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 2,105 $2,444,304
Xarelto Rivaroxaban Brand 1,800 $2,134,189
Entresto Sacubitril/Valsartan Brand 630 $841,878
Multaq Dronedarone Hcl Brand 241 $359,825
Farxiga Dapagliflozin Propanediol Brand 357 $347,010
Jardiance Empagliflozin Brand 173 $235,498
Flecainide Acetate Generic 673 $37,842
Inpefa Sotagliflozin Brand 37 $26,952
Ranolazine Er Ranolazine Brand 65 $11,656
Amiodarone Hcl Generic 858 $11,207

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$600,430

Medicare's payments for the services billed

Medicare patients

1,470

Average age 78

Services billed

6,049

731 women, 739 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Atrial fibrillation 59%
Arthritis 55%
Heart failure 42%
Diabetes 41%
Chronic kidney disease 37%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MULTAQ
$5,167 241 —
XARELTO
$1,718 1,800 —
JARDIANCE
$233 173 —
CAMZYOS
$161 — —
ELIQUIS
$148 2,105 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

1,601 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record